280 related articles for article (PubMed ID: 15961977)
1. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
Paar WD; Poche S; Gerloff J; Dengler HJ
Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
[TBL] [Abstract][Full Text] [Related]
4. The hypoalgesic effect of tramadol in relation to CYP2D6.
Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH
Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065
[TBL] [Abstract][Full Text] [Related]
5. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
7. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH
Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820
[TBL] [Abstract][Full Text] [Related]
8. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
9. Modelling the pharmacokinetics of tramadol: on the difference between CYP2D6 extensive and poor metabolizers.
Di Patti F; Fanelli D; Pedersen RS; Giuliani C; Torricelli F
J Theor Biol; 2008 Oct; 254(3):568-74. PubMed ID: 18640130
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
12. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
13. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas NR
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
[TBL] [Abstract][Full Text] [Related]
14. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
16. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN
Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
18. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
19. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
[TBL] [Abstract][Full Text] [Related]
20. Pupillometry in healthy volunteers as a biomarker of tramadol efficacy.
Matouskova O; Slanar O; Chytil L; Perlik F
J Clin Pharm Ther; 2011 Aug; 36(4):513-7. PubMed ID: 21729116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
